Nutritional products maker Herbalife's beats Q2 adjusted EPS estimates, raises full-year guidance

Reuters
08/07
Nutritional products maker Herbalife's beats <a href="https://laohu8.com/S/QTWO">Q2</a> adjusted EPS estimates, raises full-year guidance

Overview

  • Herbalife Q2 net sales of $1.3 bln down 1.7% yr/yr, flat in constant currency

  • Adjusted EBITDA of $173.6 mln exceeds company guidance, adjusted EPS beats market estimates

  • Co raises full-year net sales and adjusted EBITDA guidance

Outlook

  • Herbalife raises full-year 2025 net sales growth guidance to (1.0)% to +3.0% YoY

  • Company increases full-year 2025 adjusted EBITDA guidance to $640 mln - $660 mln

  • Herbalife reduces full-year 2025 capital expenditures guidance to $75 mln - $95 mln

  • Company sees Q3 2025 net sales growth of +0.5% to +4.5% YoY

Result Drivers

  • PRODUCT LAUNCHES - Launch of MultiBurn supplement and beta version of Pro2col app seen as pivotal steps in innovation, per CEO Stephan Gratziani

  • CURRENCY HEADWINDS - Net sales impacted by 170 basis points of FX headwinds, flat year-over-year on constant currency basis

  • DISTRIBUTOR ENGAGEMENT - Distributor growth initiatives supported engagement but new distributor growth was flat year-over-year

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Adjusted EPS

Beat

$0.59

$0.38 (2 Analysts)

Q2 EPS

$0.48

Q2 Net Income

$49.30 mln

Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the food processing peer group is "buy."

  • Wall Street's median 12-month price target for Herbalife Ltd is $9.00, about 5.1% below its August 5 closing price of $9.46

  • The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 3 three months ago

Press Release: ID:nBw7BXRjwa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10